Rod Raynovich's  Instablog

Rod Raynovich
Send Message
Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 30 years executive experience including Abbott and JNJ and has been involved three successful start-ups. He has a B.S, from Penn State University and an MBA from... More
My company:
Raygent Capital
My blog:
raygent.com
  • Life Science Stocks Brought Down By Dysfunctional Congress 0 comments
    Dec 21, 2012 2:44 PM | about stocks: ILMN, CEMI, IBB

    End of Year Rally Crushed By Turmoil in Budget Talks

    Up until late yesterday investors were optimistic about a budget deal with the "Kubuki Theater" Congress. You have heard enough about the fiscal cliff and non-starter proposals to avert the fiscal cliff so let this link suffice. Up until now the market expected some deal to be struck but optimism has waned. With two hours trading left the market is off its lows but down over 1% on heavy volume.

    Most recently we reiterated a number of buys in our Diagnostics and Tools portfolio and many of these focus stocks took a hit today. Among the stalled DX plays today are Alere (NYSE:ALR) down 1% , Cepheid (NASDAQ:CPHD) down 0.7% and Quidel (NASDAQ:QDEL) down 1.76%. Thinly traded Response Genetics (NASDAQ:RGDX) took a big 7% hit. High volume selling and profit taking has hurt the technicals of Exact Sciences (EXAS $10.6) and Sequenom (SQNM $4.66) both down over 3%.

    Chembio (CEMI $5.55) up 23%, a small cap diagnostic player broke out today on news of FDA approval of its point of care HIV diagnostic test.

    Illumina (ILMN $56.60) up 0.7% continued its momentum as the Roche bid rumor resurfaced. Illumina was added to our focus list at $27.20 and reiterated in the $45 range.

    Rayno Biopharmaceutical stocks were hit harder with many big winner momentum plays off more than 2%. Using the logic of the AAPL stock decline due to profit taking we have been perplexed by the continued strength of big biotech winners such as Medivation (MDVN $52) and Regeneron (REGN $172.48). But Alexion (ALXN $93.90) is well off its October high of $119 and the sector overall remains lower that the October highs.

    Take a little off the high fliers and remain cautious.

    Disclosure: I am long ILMN, QDEL, ALR.

    Stocks: ILMN, CEMI, IBB
Back To Rod Raynovich's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.